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Eﬀ ect of lowering blood pressure on cardiovascular events 
and mortality in patients on dialysis: a systematic review 
and meta-analysis of randomised controlled trials
Hiddo J Lambers Heerspink, Toshiharu Ninomiya, Sophia Zoungas, Dick de Zeeuw, Diederick E Grobbee, Meg J Jardine, Martin Gallagher, 
Matthew A Roberts, Alan Cass, Bruce Neal, Vlado Perkovic
Summary
Background Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. 
Although several trials have shown the cardiovascular beneﬁ ts of lowering blood pressure in the general population, 
there is uncertainty about the eﬃ  cacy and tolerability of reducing blood pressure in patients on dialysis. We did a 
systematic review and meta-analysis to assess the eﬀ ect of blood pressure lowering in patients on dialysis.
Methods We systematically searched Medline, Embase, and the Cochrane Library database for trials reported between 
1950 and November, 2008, without language restriction. We extracted a standardised dataset from randomised 
controlled trials of blood pressure lowering in patients on dialysis that reported cardiovascular outcomes. Meta-
analysis was done with a random eﬀ ects model. 
Findings We identiﬁ ed eight relevant trials, which provided data for 1679 patients and 495 cardiovascular events. 
Weighted mean systolic blood pressure was 4·5 mm Hg lower and diastolic blood pressure 2·3 mm Hg lower in 
actively treated patients than in controls. Blood pressure lowering treatment was associated with lower risks of 
cardiovascular events (RR 0·71, 95% CI 0·55–0·92; p=0·009), all-cause mortality (RR 0·80, 0·66–0·96; p=0·014), and 
cardiovascular mortality (RR 0·71, 0·50–0·99; p=0·044) than control regimens. The eﬀ ects seem to be consistent 
across a range of patient groups included in the studies.
Interpretation Treatment with agents that lower blood pressure should routinely be considered for individuals 
undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population.
Funding National Health and Medical Research Council of Australia Program.
Introduction 
Worldwide, many hundreds of thousands of people 
receive dialysis on a continuing basis because of severe 
and irreversible chronic kidney disease. These patients 
are at increased risk of cardiovascular mortality and 
morbidity compared with the general population.1 Every 
year, between 10% and 20% of all patients on dialysis die, 
with around 45% of these deaths attributed to 
cardiovascular causes.2
Blood pressure is usually raised in patients receiving 
dialysis, possibly because the role of the kidneys in blood 
pressure homoeostasis is impaired; chronic volume 
overload and a range of other factors might also 
contribute to high blood pressure. Several clinical trials 
and meta-analyses3–7 have shown the cardiovascular 
beneﬁ ts of lowering blood pressure in the general 
population and in patients with early kidney disease; 
therefore, reduction of blood pressure is an attractive 
therapeutic target for patients on dialysis. However, the 
eﬃ  cacy and safety of lowering blood pressure in this 
patient population are still uncertain. Observational 
studies in patients on dialysis have suggested a time-
dependent association between blood pressure levels 
and cardiovascular outcomes, with low blood pressure 
being associated with higher mortality rates in the short 
term, but lower mortality rates in the long term. These 
ﬁ ndings probably reﬂ ect a confounding of the short-
term association attributable to reverse causation.8,9 
Although most of the previous trials on blood pressure 
lowering have systematically excluded patients on 
dialysis, the ﬁ rst trials done in this patient population 
reported conﬂ icting results.10,11 We therefore undertook a 
systematic review and meta-analysis to assess the eﬀ ect 
of treatments that reduce blood pressure in patients 
receiving maintenance dialysis.
Methods
Search strategy and selection criteria
We did a systematic review of the available literature in 
accordance with the QUORUM guidelines for the 
conduct of meta-analyses of intervention studies.12 
Relevant studies were identiﬁ ed by searches of Medline 
via Ovid (from 1950 up to November, 2008), Embase 
(from 1966 up to November, 2008), and the Cochrane 
Library database (Cochrane Central Register of Controlled 
Trials; no date restriction), with relevant text words and 
medical subject headings that included all spellings of 
antihypertensive agents, “renal dialysis”, “kidney failure”, 
and “cardiovascular disease” (see webappendix p 3 for 
complete search strategy). The search was limited to 
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randomised controlled trials but was without language 
restriction. Reference lists from identiﬁ ed trials and 
review articles were manually scanned to identify any 
other relevant studies. A search of the ClinicalTrials.gov 
website was also done to identify randomised studies 
that were registered as completed but not yet published. 
Requests for original data were made by contacting 
authors or principal investigators.
The literature search, data extraction, and quality 
assessment were done independently by two reviewers 
(HJLH and TN) by use of a standardised approach. All 
completed randomised controlled trials that assessed the 
eﬀ ects of agents that lower blood pressure on cardiovascular 
outcomes in adult patients on maintenance dialysis were 
eligible for inclusion. Outcomes analysed were all 
cardiovascular events, as deﬁ ned by the authors of each 
study, all-cause mortality, and cardiovascular mortality.
Data extraction and quality assessment
The two reviewers extracted data on patient characteristics 
(age, sex, systolic and diastolic blood pressure, duration 
on dialysis, diabetes, hypertension, and heart failure 
status), follow-up duration, inclusion and exclusion 
criteria, rates of outcome events, type and dose of blood 
pressure lowering agent, mean diﬀ erence in systolic and 
diastolic blood pressure during the trial, and summary 
measures of eﬀ ects on outcomes of blood pressure 
treatment. The quality of the report was judged by 
concealment of treatment allocation, similarity of both 
groups at baseline in terms of prognostic factors, 
eligibility criteria, blinding of outcome assessors, 
completeness of follow-up, and intention-to-treat 
analysis.13 We also used the Jadad score to quantify study 
quality.14 Any disagreement in abstracted data was 
resolved by a third reviewer (VP).
Statistical analysis
Individual study risk ratios (RRs) and 95% CIs were 
calculated before data pooling. The weighted mean blood 
pressure reduction was calculated by multiplying the 
blood pressure diﬀ erence in each study by the total 
number of patients in each study, and then dividing by 
the number of studies. Summary estimates of RRs were 
obtained by use of a random eﬀ ects model. The 
percentage of variability across studies attributable to 
heterogeneity beyond chance was estimated by use of the 
I² statistic.15 Potential publication bias was assessed with 
the Egger test and represented graphically by use of Begg 
funnel plots of the natural log of the RR versus its 
standard error.16 Potential heterogeneity in estimates of 
treatment eﬀ ect attributable to each potential source of 
heterogeneity was explored by univariate meta-
regression.15 Additionally, we investigated possible 
sources of heterogeneity by comparing summary results 
obtained from subsets of studies grouped by number of 
events, duration of follow-up, patient status, and class of 
blood pressure lowering agent used. A two-sided p value 
of less than 0·05 was judged signiﬁ cant for all analyses. 
All statistical analyses were done with STATA, version 9.
Role of the funding source
The sponsor had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Figure 1 shows how studies were selected. Seven 
randomised trials that provided information on a total of 
1571 patients and 495 cardiovascular events were eligible 
for inclusion,10,11,17–21 and one further randomised trial in 
108 patients that reported a hazard ratio with conﬁ dence 
intervals for cardiovascular events could also be 
included.22 Six of the trials were published in peer-
reviewed journals10,11,17,19–21 and two were presented at 
international scientiﬁ c meetings.18,22 Most other studies 
identiﬁ ed by our search were randomised trials that 
provided information on intermediate clinical measures 
for cardiovascular disease, but no data on the outcomes 
as deﬁ ned for our systematic review.
1152 excluded
           479 not original investigation (eg, review)
                6 not human studies
           190 no dialysis patients
              18 trial of paediatric population
           357 no relevant outcomes
              75 not randomised controlled trial
              27 other publication from same trial
1259 titles and abstracts identiﬁed through 
           database searches
           437 Medline
           789 Embase
              33 Cochrane Library
1177 abstracts screened
8 articles included in review and 
    meta-analysis
28 full-text articles selected for detailed 
      assessment
3 articles identiﬁed from other source*
20 excluded
         1 not randomised controlled trial
         2 no dialysis patients
       17 no relevant outcomes
82 duplicate studies excluded
Figure 1: Identiﬁ cation process for eligible studies
*Searches on http://www.ClinicalTrials.gov.
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Table 1 summarises the characteristics of the included 
randomised trials. Four trials were done in Europe,10,11,18,21 
three in Japan,19,20,22 and one in Hong Kong.17 Of the eight 
trials, three assessed the eﬀ ects of angiotensin-receptor 
blockers (ARBs),18–20 two assessed an angiotensin-
conver ting enzyme (ACE) inhibitor,11,17 two a β blocker,10,22 
Inclusion criteria Active 
treatment
Control Design Cardiovascular outcome Number 
of 
patients
Men, n 
(%)
Age, years 
(mean)
Patients 
with 
diabetes, 
n (%)
Number of 
cardiovascular 
events
Cice et al 
(2003)10
Uraemic patients with 
dilated 
cardiomyopathy; stable 
weight (<2·5 kg change 
before enrolment)
Carvedilol 
50 mg/day
Matched 
placebo
Randomised, 
placebo-controlled, 
double-blind trial 
(unblinded for 
second 12 months)
Myocardial infarction, 
cardiovascular death
114 69 (61%) 55 NR 56
Li et al 
(2003)17
Peritoneal dialysis with 
residual glomerular 
ﬁ ltration rate 
≥2 mL/min /1·73 m2; 
blood pressure 
≥120/70 mm Hg; no 
ACE inhibitor/ARB use 
for at least 6 months 
before enrolment
Ramipril 
5 mg/day
Conventional 
treatment
Randomised, 
open-label trial
Myocardial infarction, 
stroke, peripheral 
vascular disease, 
cardiovascular death
60 38 (63%) 59 28 (47%) 10
Cice et al 
(2006)18
Congestive heart failure 
NYHA class II and III; 
left ventricular ejection 
fraction <40%
Telmisartan 
80 mg/day
Matched 
placebo 
Randomised, 
placebo-controlled, 
double-blind trial
Cardiovascular mortality 303 158 (52%) 59 98 (32%) 134
Takahashi 
et al 
(2006)19
≥35 years; stable 
interdialytic weight; 
post-haemodialytic 
cardiothoracic ratio on 
chest radiograph 
<50% in men or 35% in 
women
Candesartan 
16–32 mg/day
Conventional 
treatment
Randomised, 
open-label, blinded 
endpoint trial
Myocardial infarction, 
unstable angina pectoris 
or heart failure needing 
hospital admission, 
severe arrhythmia, 
sudden death
80 47 (59%) 61 26 (33%) 24
Zannad et al 
(2006)11
50–80 years; 
haemodialyis for at 
least 6 months three 
times a week; left 
ventricular hypertrophy 
within 3 months of 
enrolment
Fosinopril 
20 mg/day
Matched 
placebo
Randomised, 
placebo-controlled, 
double-blind trial
Myocardial infarction, 
stroke, hospital 
admission for heart 
failure, unstable angina 
pectoris, 
revascularisation, cardiac 
arrest, cardiovascular 
death
397 208 (52%) 67 124 (31%) 127
Nakao et al 
(2007)22
Haemodialysis for at 
least 6 months; BNP 
>200 pg/mL; hANP 
<150 pg/mL; left 
ventricular hypertrophy
Carvedilol 
20 mg/day
Matched 
placebo
Randomised, 
open-label, 
placebo-controlled 
trial
Myocardial infarction, 
stroke, hospital 
admission for heart 
failure, peripheral 
vascular disease, 
arrhythmia, 
cardiomyopathy,  
sudden cardiac arrest, 
cardiovascular death
108 64 (59%) 60 52 (48%) NR
Suzuki et al 
(2008)20
30–80 years; 
haemodialyis for at 
least 12 months; 
systolic blood pressure 
>160 mm Hg or 
>150 mm Hg if taking 
antihypertensive 
agents
Candesartan 
12 mg/day,
losartan 
100 mg/day, or
valsartan 
160 mg/day
Conventional 
treatment
Randomised 
open-label trial
Myocardial infarction, 
stroke, CABG, 
percutaneous coronary 
intervention, congestive 
heart failure, 
cardiovascular death
366 216 (59%) 60 187 (51%) 93
Tepel et al 
(2008)21
≥18 years; 
haemodialysis for at 
least 3 months; blood 
pressure 
≥140/90 mm Hg
Amlodipine 
10 mg/day
Matched 
placebo
Randomised, 
placebo-controlled, 
double-blind trial
Myocardial infarction, 
CABG, ischaemic stroke, 
peripheral vascular 
disease needing 
amputation, all-cause 
mortality
251 159 (63%) 61 73 (29%) 51
ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker. BNP=brain natriuretic peptide. CABG=coronary artery bypass graft. hANP=human atrial natriuretic peptide. NR=not reported. 
NYHA=New York Heart Association.
Table 1: Characteristics of studies reporting the eﬀ ects of blood pressure lowering agents for prevention of cardiovascular events in patients on maintenance dialysis
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and one a calcium-channel blocker.21 The mean baseline 
systolic blood pressure in the contributing studies ranged 
from 134 mm Hg to 155 mm Hg; for diastolic blood 
pressure the range was 75 mm Hg to 93 mm Hg. Three 
studies included patients on the basis of a diagnosis of 
hypertension;19–21 the other ﬁ ve studies enrolled patients 
with and without hypertension.
The components of the cardiovascular composite 
endpoint diﬀ ered across the studies. Myocardial infarction 
and cardiovascular mortality were the most frequently 
included components, three trials included hospital 
admission for heart failure as an endpoint,11,19,22 and one 
trial included congestive heart failure.20 Study follow-up 
period ranged from 12 months to 36 months. Six trials 
provided information about mean follow-up blood 
pressure diﬀ erence between treatment groups.10,11,17,19,20,22 
The weighted mean diﬀ erence in blood pressure during 
follow-up between active and control treatment across all 
trials was –4·5 mm Hg for systolic and –2·3 mm Hg for 
diastolic blood pressure (ﬁ gure 2). Quality assessment 
showed that few studies described concealment of 
allocation or blinding of outcome assessor. Two of the 
eight trials did not describe whether the analyses were by 
intention to treat (webappendix p 1).20,22 Across all published 
trials the mean Jadad score was 3·1 (maximum 5).
Overall, treatment with blood pressure lowering drugs 
was associated with a lower risk of cardiovascular events 
compared with control regimens (RR 0·71, 95% CI 
0·55–0·92; p=0·009; ﬁ gure 2). Exclusion of the two 
unpublished trials did not alter the ﬁ ndings (RR 0·64, 
0·43–0·94; p=0·022) and there was no evidence of 
publication bias (Egger’s test p=0·287; webappendix p 2). 
There was evidence of heterogeneity in the magnitude 
of the eﬀ ect across the included studies (I²=67·5%; 
p=0·003; figure 2). Figure 3 shows the results of the 
subgroup analyses. We identiﬁ ed no evidence of 
heterogeneity of eﬀ ect in all subgroup analyses (all values 
for heterogeneity p>0·068) apart from when studies were 
divided on the basis of inclusion or exclusion of hospital 
admission for heart failure in the composite endpoint 
(p=0·006). For every trial subgroup the point estimate of 
eﬀ ect was suggestive of beneﬁ t for this outcome. 
Univariate meta-regression analysis showed the presence 
of heterogeneity of eﬀ ect by inclusion of heart failure in 
the composite outcome (p=0·006) and also suggested an 
eﬀ ect of the number of events recorded in the trial 
(p=0·031) and the mean age of the trial participants 
(p=0·011). Exclusion of the trial that assessed peritoneal 
dialysis patients17 did not substantially change the overall 
eﬀ ect estimate (RR 0·70, 0·53–0·91).
Of the eight trials, seven studies (1571 patients) provided 
information on all-cause mortality and ﬁ ve studies 
(1240 patients) provided information on cardiovascular 
mortality. The risks for all-cause mortality (RR 0·80, 0·66–
0·96; p=0·014) and cardiovascular mortality (RR 0·71, 
0·50–0·99; p=0·044) were lower for blood pressure 
lowering treatments than for control regimens (ﬁ gure 4). 
Numbers of events/patients
Active treatment Control
SBP/DBP
diﬀerence (mm Hg)
Risk ratio
(95% CI)
Risk ratio
(95% CI)
0·3
Favours active
treatment
Favours
control
0·5 1·0 2·0
Li et al (2003)17
Takahashi et al (2006)19
Tepel et al (2008)21
Cice et al (2003)10
Suzuki et al (2008)20
Nakao et al (2007)22
Zannad et al (2006)11
Cice et al (2006)18
Overall
Test for heterogeneity: l2=67·5%, Q=21·5, p=0·003
Excluding unpublished studies
Test for heterogeneity: l2=73·7%, Q=19·0, p=0·002
5/30
7/43
19/123
17/58
34/183
NA/57
67/196
59/151
208/841
5/30
17/37
32/128
39/56
   59/183
NA/51
60/201
75/152
287/838
+0·7/–3·5
+3·0/0·0
–9·0/NA
–10·5/–7·0
–2·3/–0·5
–7·3/–6·3
–3·9/–1·7
NA
–4·5/–2·3
1·00 (0·34–2·92)
0·43 (0·21–0·89)
0·60 (0·36–0·99)
0·42 (0·27–0·65)
0·58 (0·40–0·83)
0·97 (0·67–1·34)
1·12 (0·84–1·49)
0·79 (0·61–1·02)
0·71 (0·55–0·92)
0·64 (0·43–0·94)
Figure 2: Risk of cardiovascular events for blood pressure lowering treatment versus control regimens
DBP=diastolic blood pressure. SBP=systolic blood pressure. NA=not applicable. The overall mean diﬀ erence in 
systolic and diastolic blood pressure in the active treatment group compared with the control group is also shown. 
Negative values indicate lower mean follow-up blood pressure in the active treatment group.
Number of patients
Number of events
Duration of follow-up
Years on dialysis
Ethnicity
Hypertensive patients
Heart failure patients
Study drug
Endpoints
Study quality
Number of 
studies
Risk ratio 
(95% CI)
Favours active 
treatment
Favours 
control
p value for 
heterogeneity
0·63 (0·37–1·08)
0·77 (0·57–1·04)
0·51 (0·38–0·68)
0·81 (0·57–1·14) 
0·77 (0·51–1·14)
0·65 (0·48–0·88)
0·58 (0·44–0·76)
0·79 (0·56–1·13)
0·71 (0·48–1·05)
0·70 (0·47–1·04)
0·56 (0·43–0·74)
0·81 (0·59–1·12)
0·59 (0·32–1·09)
0·76 (0·56–1·04)
0·64 (0·38–1·07)
0·76 (0·56–1·04)
0·54 (0·42–0·69)
0·87 (0·66–1·14)
0·59 (0·32–1·09)
0·76 (0·56–1·04)
4
4
4
3
5
3
4
4
4
4
3
5
2
6
5
3
4
4
2
6
  0·524
  0·068
  0·452
  0·233
  0·944
  0·133
  0·432
  0·565
 0·006
  0·432
0·3 0·5 1·0 2·0
≤200 patients
>200 patients
≤75 events
>75 events
≤24 months
>24 months
≤4 years
>4 years
Asian
European
Yes
No or not speciﬁed
Yes
No or not speciﬁed
ACE inhibitor/ARB
Non-ACE inhibitor/ARB
No heart failure
Heart failure
Jadad score=2
Jadad score ≥3
Risk ratio
(95% CI)
Figure 3: Subgroup analyses for the eﬀ ects of blood pressure lowering agents on cardiovascular events
ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker.
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There was no strong evidence of heterogeneity of eﬀ ect 
size among the studies for the outcomes of all-cause 
mortality or cardiovascular mortality. 
Two studies used an active run-in design, in which 
patients who did not tolerate the study drug during a 
preliminary phase were not randomised to treatment or 
placebo.10,11 14% and 1% of patients were excluded during 
the run-in periods of these trials (table 2). Five studies 
reported information about study treatment 
discontinuation rates.10,17,18,20,21 Overall, the proportion of 
patients who stopped taking study medication was low 
and did not diﬀ er substantially between active treatment 
and control groups (table 2).
Discussion
Individuals undergoing dialysis are at increased risk of 
death and cardiovascular events but so far no treatments 
proven to reduce this risk have been available to patients 
and clinicians. Interventions such as lipid lowering,23 
dialysis prescription modiﬁ cation,24 homocysteine 
lowering,25–27 mineral metabolism modiﬁ cation,28 and 
haemoglobin normalisation29 have been assessed in 
randomised trials and systematic reviews, but there is no 
clear evidence to show that any of these approaches 
reduces the risk of death or major cardiovascular events. 
In this meta-analysis of randomised trials, we have shown 
that treatment with agents that lower blood pressure 
reduces cardiovascular morbidity and mortality in patients 
on maintenance dialysis. The eﬀ ects are consistent with 
or without the presence of hypertension and other 
comorbidities and across a range of drug classes.
The optimum blood pressure goals for dialysis patients 
have not been deﬁ ned. The Kidney Disease Outcomes 
Quality Initiative recommends a predialysis blood 
pressure goal of below 140/90 mm Hg.30 The rationale for 
this recommendation is largely based on extrapolation of 
blood pressure targets from studies done in the non-
dialysis population with normal renal function. Here, we 
found that the beneﬁ t of blood pressure lowering drugs 
was similar in trials that did and did not select participants 
on the basis of raised baseline blood pressure levels.
Drugs that lower blood pressure might increase the 
risk of intradialytic hypotension, and previous 
observational studies have suggested that this adverse 
event might be associated with an increased risk of all-
cause mortality.31 However, we found that blood pressure 
lowering was well tolerated, with few participants 
excluded during the active run-in phase of the two trials 
that used this design, and no consistent evidence of 
higher dropout rates in the active treatment groups than 
in the control groups of the studies. Additionally, the risk 
of death and other serious outcomes was reduced by the 
use of agents that lower blood pressure. Randomised 
controlled trials that compare the eﬀ ects of diﬀ erent 
intensities of blood pressure lowering on the risk of 
subsequent cardiovascular outcomes in patients on 
dialysis would provide further insight, but until further 
data are available, it would seem reasonable to consider 
treating patients on dialysis with some form of blood 
pressure lowering treatment, if they are able to tolerate 
the drug.
This analysis is not able to separate out the eﬀ ects of 
blood pressure lowering for speciﬁ c drug classes. The 
results do not show any diﬀ erences in cardiovascular 
events caused by diﬀ erent drug classes; however, the 
Numbers of events/patients
Active treatment
All-cause mortality
Li et al (2003)17
Takahashi et al (2006)19
Tepel et al (2008)21
Cice et al (2003)10
Suzuki et al (2008)20
Nakao et al (2007)22
Zannad et al (2006)11
Cice et al (2006)18
Overall
Test for heterogeneity: l2=30·0%, Q=8·57, p=0·20
Cardiovascular mortality
Li et al (2003)17
Takahashi et al (2006)19
Tepel et al (2008)21
Cice et al (2003)10
Suzuki et al (2008)20
Nakao et al (2007)22
Zannad et al (2006)11
Cice et al (2006)18
Overall
Test for heterogeneity: l2=54·6%, Q=8·8, p=0·07
Control
3/30
0/43
15/123
30/58
25/183
NR
52/196
88/151
213/784
2/30
NR
NR
17/58
12/183
NR
31/196
59/151
121/618
2/30
NR
NR
38/56
20/183
NR
30/201
75/152
165/622
2/30
7/37
20/128
41/56
38/183
NR
49/201
111/152
268/787
1·40 (0·30–6·55)
0·06 (0·00–0·97)
0·72 (0·39–1·30)
0·71 (0·53–0·95)
0·66 (0·41–1·04)
..
1·09 (0·78–1·52)
0·80 (0·68–0·94)
0·80 (0·66–0·96)
1·00 (0·15–6·64)
..
..
0·43 (0·28–0·67)
0·60 (0·30–1·19)
..
1·05 (0·67–1·68)
0·80 (0·61–1·02)
0·71 (0·50–0·99)
Risk ratio
(95% CI)
Risk ratio
(95% CI)
Favours active 
treatment
0·3 0·5 1·0 2·0
Favours
control
Figure 4: Risk of all-cause mortality and cardiovascular mortality for blood pressure lowering treatment 
versus control regimens
NR=not reported.
Active agent Active 
run-in*
Excluded 
during run-in
Patients who discontinued therapy
Active treatment Control treatment
Cice et al (2003)10 β blocker Yes 18/132 (14%) 11/58 (19%) 7/56 (13%)
Li et al (2003)17 ACE inhibitor No N/A 5/30 (17%) 0/30 (0%)
Cice et al (2006)18 ARB No N/A 20/151 (13%) 16/152 (11%)
Takahashi et al (2006)19 ARB NR N/A NR NR
Zannad et al (2006)11 ACE inhibitor Yes 6/417 (1%) NR NR
Nakao et al (2007)22 β blocker No N/A NR NR
Suzuki et al (2008)20 ARB No N/A 3/183 (2%) 3/183 (2%)
Tepel et al (2008)21 Calcium-channel 
blocker
No N/A 41/123 (33%) 43/128 (34%)
ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker. N/A=not applicable. NR=not reported. Data 
are n/N (%). *In the two studies with a preliminary run-in phase, all patients received study drug to determine before 
randomisation which patients were unable to tolerate the drug. Only patients who were able to tolerate the drug were 
randomly assigned to receive either treatment or placebo. In Zannad et al,11 six of 417 recruited patients were excluded 
after the run-in period because of symptomatic hypertension. Finally, 397 patients were randomised. 
Table 2: Study treatment discontinuation rates
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statistical power to reliably compare drug classes was 
small. The data suggest that renin-angiotensin-system 
blockers, β blockers, and calcium-channel blockers are 
all suitable for use in patients on dialysis. Drugs such 
as α blockers and centrally acting agents should 
probably be viewed as secondary choices in the absence 
of randomised studies. Although the two studies of 
ACE inhibitors did not show beneﬁ cial eﬀ ects of this 
treatment, it is unlikely that these agents have diﬀ erent 
eﬀ ects from the other classes studied because the 
negative result came from a single trial and this result 
might have arisen by chance. Furthermore, ACE 
inhibitors have similar eﬃ  cacy to other drug classes, 
especially ARBs, in the general population.32 Head-to-
head studies that compare diﬀ erent classes of blood 
pressure lowering agents have not been done in patients 
undergoing dialysis; however, trials in the general 
population have not shown markedly diﬀ erent eﬀ ects 
between drug classes.5 In the absence of further data in 
patients on dialysis, the choice of blood pressure 
lowering agents should be made on the grounds of 
general tolerability, side-eﬀ ect proﬁ les, and other 
patient variables.
Volume overload is an important contributor in the 
pathogenesis of high blood pressure in patients 
undergoing dialysis. Results from recent studies show 
that volume control in haemodialysis patients improves 
blood pressure control.33 Since few data on the 
management of volume status during dialysis were 
provided by the trials investigated here, we were unable 
to assess the eﬀ ect of this variable.
The blood pressure reduction achieved by patients 
varied widely among the trials. This variation might be 
related to the study population or class of drug used, but 
could also be the consequence of the variability in blood 
pressure measurement and the absence of ﬁ rm criteria 
that deﬁ ne how and when to measure blood pressure. 
Blood pressure is very sensitive to dialysis and variations 
in the timing of its measurement might lead to large 
diﬀ erences in the reading recorded. The diﬀ erences in 
blood pressure seen in the trials included in this analysis 
should therefore be interpreted with some caution.
The strengths of this systematic review and meta-
analysis are the rigorous methodology, the importance of 
the clinical question, and the magnitude of the beneﬁ ts 
seen. The limitations include the small number and size 
of the studies included, the limited statistical power of 
methods based on tabular data to investigate sources of 
heterogeneity, and our inability to obtain the full results 
of all completed studies.
Thus, treatment with agents that lower blood pressure 
should routinely be considered for patients undergoing 
dialysis to help prevent cardiovascular events and 
mortality. If our data are applied to a broad population of 
patients on dialysis with an annual mortality rate of about 
10%, we calculate that blood pressure lowering treatment 
could prevent two of the ten deaths expected to occur in 
every 100 patients per year. This absolute beneﬁ t will be 
greater for individuals at higher absolute risk, and is 
much greater than that reported for many other 
interventions in routine use.
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